

If you or someone close to you is interested in taking part in **SIGNAL** or you would like additional information, please contact a site near you or the Huntington Study Group (HSG):



Call: 1-800-487-7671

Email: info@hsglimited.org

Visit: huntingtonstudygroup.org

Heather Ward, Research Coor.
VCU Parkinson's and Movement Disorders
Center
Heather.ward@vcuhealth.org
804-382-0076



*Reimbursement for time spent during
in-person visits*  *Reimbursement for reasonable
travel and lodging costs*  *Study related medical care,
tests, and study drug provided at no cost*

NOTE: VX15 has not been approved by the FDA.

Potential benefits of the drug for HD patients are

being investigated with the **SIGNAL** trial.




A New Investigational Approach to Early Treatment of Huntington Disease

SIGNAL is a Phase 2 research trial for people who are at risk for Huntington Disease (HD) and have early signs of HD. The study will assess the **safety, tolerability, and effectiveness of VX15** (a novel monoclonal antibody).

Find a Site Near You:

Birmingham, AL	New York, NY
LaJolla, CA	Rochester, NY
San Francisco, CA	Durham, NC
Aurora, CO	Winston-Salem, NC
Washington, DC	Cincinnati, OH
Atlanta, GA	Columbus, OH
Indianapolis, IN	Toledo, OH
Iowa City, IA	Nashville, TN
Louisville, KY	Houston, TX
Boston, MA	Burlington, VT
Ann Arbor, MI	Richmond, VA
St. Louis, MO	Seattle, WA
	Vancouver, BC





Why study this antibody in individuals at risk for and with early signs of HD?

- If given early it may delay onset or slow the progression of HD
- This monoclonal antibody is a class of drug that binds to and blocks a molecule that may cause inflammation in the brains of individuals who develop HD as seen in animal models
- It may protect against the inflammation that has been shown to affect the thinking, movement, and behaviors that impact the daily activities of individuals with HD

Advances in HD treatment need your participation

What is different about this research trial?

- First-time use of a monoclonal antibody for potential treatment of HD
- Once-a-month study drug delivery through 60-minute (approximately) intravenous infusion
- Use of advanced brain scan techniques and analyses (MRI and PET)

Join the Huntington Study Group and Vaccinex **SIGNAL** team and play a role in researching a new approach to HD treatment that may change the course of the disease.

We are looking for people who:

- Are at risk for developing HD
- Have undergone genetic testing
- Are thought to be in the early stages of HD
- Are able to undergo brain scans (MRI and PET)
- Are able to undergo lumbar puncture to collect cerebrospinal fluid (not required to enroll)
- Are able to commit to once/month study visits
- Are 21 years of age or older

Your physician can guide you as to whether you are a candidate for this study.

